Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 795-799
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.795
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.795
Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine
Umar Wazir, Kefah Mokbel, The London Breast Institute, Princess Grace Hospital, London W1U 5NY, United Kingdom
Author contributions: Wazir U and Mokbel K contributed equally to this work.
Supported by Grants from the Breast Cancer Hope Foundation (London, United Kingdom)
Correspondence to: Kefah Mokbel, Professor, The London Breast Institute, Princess Grace Hospital, 45 Nottingham Place, London W1U 5NY, United Kingdom. kefahmokbel@hotmail.com
Telephone: +44-207-9082040 Fax: +44-207-9082275
Received: June 23, 2014
Revised: August 19, 2014
Accepted: September 16, 2014
Published online: December 10, 2014
Processing time: 171 Days and 14.3 Hours
Revised: August 19, 2014
Accepted: September 16, 2014
Published online: December 10, 2014
Processing time: 171 Days and 14.3 Hours
Core Tip
Core tip: Recurrence score, Prosigna and EndoPredict (EP) currently have the most convincing evidence available, of which Prosigna and EP have a significant degree of external validation. In terms of cost and turnover, EP has an advantage over its competitors, being designed to be performed at a local laboratory rather than at a central facility. The results of the MINDACT and TailoRx trials are awaited.